GeneTex
United States (US)

Human Soluble TNF Receptor I protein (active)

Cat No. GTX29980-pro

Species Human
APPLICATION

Application Note

The biological activity of sTNF-RI was determined by its inhibitory effect of the TNF-α mediated cytotoxicity in murine L-929 cells. The ED₅₀ for the effect in the presence of 0.25 ng/ml of recombinant TNF-α, is 0.05 mg/ml.

Calculated MW

50.49 kDa. ( Note )
PROPERTIES

Form

Lyophilized powder

Buffer

Lyophilized from 5 mM Tris (pH 8.0). Reconstitute with 5 mM Tris (pH 8.0) to 1 mg/ml.

Storage

Store at -20ºC or below. After reconstitution, keep as concentrated solution. Aliquot and avoid freeze-thaw cycles.

Expression System

E. coli

Purity

> 98% by SDS-PAGE and HPLC.

Endotoxin

< 1 EU/μg

Conjugation

Unconjugated

Note

For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

TNF receptor superfamily member 1A , CD120a , FPF , TBP1 , TNF-R , TNF-R-I , TNF-R55 , TNFAR , TNFR1 , TNFR55 , TNFR60 , p55 , p55-R , p60

Background

The protein encoded by this gene is a member of the TNF-receptor superfamily. This protein is one of the major receptors for the tumor necrosis factor-alpha. This receptor can activate NF-kappaB, mediate apoptosis, and function as a regulator of inflammation. Antiapoptotic protein BCL2-associated athanogene 4 (BAG4/SODD) and adaptor proteins TRADD and TRAF2 have been shown to interact with this receptor, and thus play regulatory roles in the signal transduction mediated by the receptor. Germline mutations of the extracellular domains of this receptor were found to be associated with the autosomal dominant periodic fever syndrome. The impaired receptor clearance is thought to be a mechanism of the disease. [provided by RefSeq, Jul 2008]

Database

Research Area

Package List Price ($)
$ 279